Related Experiment Video

Updated: May 10, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition

Julian Segura1, Jorge Salazar, Luis M Ruilope

  • 1Hospital 12 de Octubre, Department of Nephrology, Hypertension Unit , Av. Córdoba s/n, 28041 Madrid, Spain.

Expert Opinion on Investigational Drugs
|June 5, 2013
PubMed

Insights

New drug LCZ696 shows promise for treating high blood pressure and cardiovascular disease. This novel medication combines a neprilysin inhibitor with an angiotensin receptor blocker for improved efficacy.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Nephrology

Background:

  • Cardiovascular disease is a leading global cause of mortality.
  • Elevated blood pressure is a primary modifiable risk factor, contributing to millions of deaths annually.
  • There is a continuous need for novel therapeutics to manage cardiovascular and renal diseases.

Purpose of the Study:

  • To review available data on LCZ696, a novel compound in development.
  • To assess the efficacy and tolerability of LCZ696 for arterial hypertension.
  • To explore preliminary evidence for LCZ696 in cardiovascular disease treatment.

Main Methods:

  • Literature review of studies published within the last five years.
  • Searches conducted using PubMed with relevant keywords.
  • Focus on data pertaining to LCZ696, the first-in-class angiotensin receptor neprilysin inhibitor.

Main Results:

  • LCZ696 demonstrates positive efficacy in managing arterial hypertension.
  • The compound exhibits a favorable tolerability profile.
  • Preliminary data suggest potential benefits for cardiovascular disease treatment.

Conclusions:

  • LCZ696 shows significant promise for the treatment of arterial hypertension.
  • Emerging data indicate LCZ696 may also be beneficial in managing cardiovascular disease.
  • The combination of neprilysin inhibition and angiotensin receptor blockade represents a novel therapeutic approach.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...